These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 31131994

  • 1. Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.
    Md Yusof MY, Vital EM, McElvenny DM, Hensor EMA, Das S, Dass S, Rawstron AC, Buch MH, Emery P, Savic S.
    Arthritis Rheumatol; 2019 Nov; 71(11):1812-1823. PubMed ID: 31131994
    [Abstract] [Full Text] [Related]

  • 2. Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study.
    Wade SD, Kyttaris VC.
    Rheumatol Int; 2021 Jun; 41(6):1115-1124. PubMed ID: 33811499
    [Abstract] [Full Text] [Related]

  • 3. Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is related with good response: 13 years real-life experience.
    Evangelatos G, Fragoulis GE, Klavdianou K, Moschopoulou M, Vassilopoulos D, Iliopoulos A.
    Rheumatology (Oxford); 2021 May 14; 60(5):2375-2382. PubMed ID: 33175958
    [Abstract] [Full Text] [Related]

  • 4. Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab.
    Heusele M, Clerson P, Guery B, Lambert M, Launay D, Lefevre G, Morell-Dubois S, Maillard H, Le Gouellec N, Hatron PY, Hachulla E.
    Clin Rheumatol; 2014 Jun 14; 33(6):799-805. PubMed ID: 24487486
    [Abstract] [Full Text] [Related]

  • 5. Rituximab-associated hypogammaglobulinaemia in ANCA-associated vasculitis and connective tissue diseases: a longitudinal observational study.
    Padoan R, Felicetti M, Gatto M, Polito P, Doria A, Schiavon F.
    Clin Exp Rheumatol; 2020 Jun 14; 38 Suppl 124(2):188-194. PubMed ID: 32441645
    [Abstract] [Full Text] [Related]

  • 6. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.
    Thiel J, Rizzi M, Engesser M, Dufner AK, Troilo A, Lorenzetti R, Voll RE, Venhoff N.
    Arthritis Res Ther; 2017 May 18; 19(1):101. PubMed ID: 28521808
    [Abstract] [Full Text] [Related]

  • 7. Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults.
    McAtee CL, Lubega J, Underbrink K, Curry K, Msaouel P, Barrow M, Muscal E, Lotze T, Srivaths P, Forbes LR, Allen C, Bernhardt MB.
    JAMA Netw Open; 2021 Feb 01; 4(2):e2036321. PubMed ID: 33533931
    [Abstract] [Full Text] [Related]

  • 8. Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study.
    Boleto G, Avouac J, Wipff J, Forien M, Dougados M, Roux C, Kahan A, Dieude P, Allanore Y.
    Semin Arthritis Rheum; 2018 Oct 01; 48(2):149-154. PubMed ID: 29548542
    [Abstract] [Full Text] [Related]

  • 9. Serious Infectious Events and Immunoglobulin Replacement Therapy in Patients With Autoimmune Disease Receiving Rituximab: A Retrospective Cohort Study.
    Stabler S, Giovannelli J, Launay D, Cotteau-Leroy A, Heusele M, Lefèvre G, Terriou L, Lambert M, Dubucquoi S, Hachulla E, Sobanski V.
    Clin Infect Dis; 2021 Mar 01; 72(5):727-737. PubMed ID: 32067031
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease.
    Tieu J, Smith RM, Gopaluni S, Kumararatne DS, McClure M, Manson A, Houghton S, Jayne DRW.
    Front Immunol; 2021 Mar 01; 12():671503. PubMed ID: 34054846
    [Abstract] [Full Text] [Related]

  • 12. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases.
    Freites Nuñez DD, Leon L, Mucientes A, Rodriguez-Rodriguez L, Font Urgelles J, Madrid García A, Colomer JI, Jover JA, Fernandez-Gutierrez B, Abasolo L.
    Ann Rheum Dis; 2020 Nov 01; 79(11):1393-1399. PubMed ID: 32769150
    [Abstract] [Full Text] [Related]

  • 13. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry.
    Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, Dougados M, Flipo RM, Godeau B, Guillevin L, Le Loët X, Hachulla E, Schaeverbeke T, Sibilia J, Baron G, Mariette X, AutoImmunity and Rituximab registry and French Society of Rheumatology.
    Arthritis Rheum; 2010 Sep 01; 62(9):2625-32. PubMed ID: 20506353
    [Abstract] [Full Text] [Related]

  • 14. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?
    Galarza C, Valencia D, Tobón GJ, Zurita L, Mantilla RD, Pineda-Tamayo R, Rojas-Villarraga A, Rueda JC, Anaya JM.
    Clin Rev Allergy Immunol; 2008 Feb 01; 34(1):124-8. PubMed ID: 18270866
    [Abstract] [Full Text] [Related]

  • 15. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
    Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, Larroche C, Soubrier M, Bouillet L, Dougados M, Fain O, Farge D, Kyndt X, Lortholary O, Masson C, Moura B, Remy P, Thomas T, Wendling D, Anaya JM, Sibilia J, Mariette X, Club Rheumatismes et Inflammation (CRI).
    Ann Rheum Dis; 2005 Jun 01; 64(6):913-20. PubMed ID: 15550531
    [Abstract] [Full Text] [Related]

  • 16. Rituximab-Induced Hypogammaglobulinemia and Risk of Infection in Neuromyelitis Optica Spectrum Disorders: A 14-Year Real-Life Experience.
    Kim SH, Park NY, Kim KH, Hyun JW, Kim HJ.
    Neurol Neuroimmunol Neuroinflamm; 2022 Sep 01; 9(5):. PubMed ID: 35853752
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and Safety of Rituximab in Systemic Lupus Erythematosus and Sjögren Syndrome Patients With Refractory Thrombocytopenia: A Retrospective Study of 21 Cases.
    Jiang B, Li T, Guo L, Shen H, Ye S, Chen S.
    J Clin Rheumatol; 2015 Aug 01; 21(5):244-50. PubMed ID: 26203828
    [Abstract] [Full Text] [Related]

  • 18. Practical use of immunosuppressive drugs in autoimmune rheumatic diseases.
    De Jesus A, Talal N.
    Crit Care Med; 1990 Feb 01; 18(2 Suppl):S132-7. PubMed ID: 2298028
    [Abstract] [Full Text] [Related]

  • 19. Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients.
    Westra J, van Assen S, Wilting KR, Land J, Horst G, de Haan A, Bijl M.
    Clin Exp Immunol; 2014 Oct 01; 178(1):40-7. PubMed ID: 24889761
    [Abstract] [Full Text] [Related]

  • 20. Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study.
    Md Yusof MY, Arnold J, Saleem B, Vandevelde C, Dass S, Savic S, Vital EM, Emery P.
    Lancet Rheumatol; 2023 Feb 01; 5(2):e88-e98. PubMed ID: 36712951
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.